This course was last updated on
September 30, 2017
CME credit has expired.


James Tauras, MD, provides his perspectives on issues related to the rapidly evolving pharmacologic management of chronic heart failure. Dr. Tauras emphasizes guideline-directed medical therapy as recommended in the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, including the real-world use of ivabradine and sacubitril/valsartan. He discusses other issues intended to help improve the health outcomes, including reducing the 30-day readmission rate, of patients with heart failure.

Content Areas

  • Benefits of switching from ACE inhibitor or ARB to sacubitril/valsartan
  • Role of aldosterone receptor agonist in heart failure with preserved ejection fraction
  • Benefits of treating hypertension in heart failure
  • Role of B-type natriuretic peptide as a biomarker
  • Precautions when prescribing ivabradine, sacubitril/valsartan
  • Strategies for reducing hospital readmission

Target Audience

This activity was developed for cardiologists, primary care physicians, nurse practitioners, nurses and other health care professionals who have an interest in heart failure.

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.


James M. Taurus, MD
James M. Taurus, MD
Assistant Professor of Medicine
CCU Director
Weiler Hospital
Montefiore Medical Center
Bronx, New York
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 ANCC Contact Hour
Opens: September 30, 2017
Expires: September 29, 2018
Target Audience: Cardiologists
Primary Care Physicians
Nurse Practitioners
Other Health Care Providers